Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in clinical relapse compared with purine antimetabolites (low certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes endoscopic recurrence compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes radiologic relapse compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes serious adverse events compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes health related quality of life compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes clinical relapse compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes radiologic relapse compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found